Stock ARMP ARMATA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse
Other stock markets
 01:30:00 18/06/2024 am IST 		5-day change 1st Jan Change
2.85 USD +5.56% Intraday chart for Armata Pharmaceuticals, Inc. +7.55% -12.04%
07/05 Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
07/05 Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Armata Pharmaceuticals : Shareholder Meeting - Form 8-K
PU
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus
AQ
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
AQ
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update
AQ
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics
AQ
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
AQ
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update
AQ
ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update
AQ
ARMATA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
ARMATA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
AQ
Armata Pharmaceuticals : Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC - Form 8-K
PU
ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)
AQ
Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage
AQ
ARMATA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. News Armata Pharmaceuticals, Inc.
  5. Press Releases